Haleon SEC Filings

Haleon plc announced an orderly Board transition: Sir Dave Lewis will resign as Chair and Director on 31 December 2025, and Vindi Banga will become Chair effective 1 January 2026.

Banga has served as Senior Independent Director since Haleon’s 2022 listing and brings extensive global consumer leadership experience, including 33 years at Unilever and roles at UK Government Investments and GSK. The Board’s decision was unanimous. Remuneration details and a successor for Senior Independent Director will be announced before his appointment takes effect.

Haleon plc reported its total voting rights and capital. As at 31 October 2025, the Company had 8,952,353,648 ordinary shares issued, including 45,930,962 held as treasury shares. After excluding treasury shares, the number of ordinary shares with voting rights is 8,906,422,686.

This voting-rights figure is the denominator shareholders and other obliged parties should use when assessing notification thresholds under the FCA’s Disclosure Guidance and Transparency Rules.

Haleon plc filed a Form 6-K announcing its Q3 2025 trading statement is available online, including on its investor site and via the UK FCA’s National Storage Mechanism.

The Company will host a short presentation and Q&A at 9:00am GMT (10:00am CET) on 30 October 2025, led by Chief Financial Officer Dawn Allen, with access via www.haleon.com/investors.

Dial-in details include UK: +44 (0) 808 189 0158; US: +1 855 979 6654; All other: +44 (0) 203 936 2999; passcode 407228. An archived webcast will be available later the same day.

Haleon plc filed a Form 6-K reporting notifications of transactions by persons discharging managerial responsibilities on 10 October 2025. The disclosure shows an allotment of £3.4352 per share for 37 matching shares as the reported trade. The notice is a regulatory disclosure under the UK Market Abuse Regulation and provides routine transparency about insider dealings. The report lists the company's well-known consumer health brands and is signed by the Company Secretary on 10 October 2025.

Haleon plc filed a Form 6-K notifying investors that Tracy Clarke, a current Non-Executive Director of Haleon, will be appointed as a Non-Executive Director of Inchcape plc effective 31 December 2025. The disclosure was made to satisfy paragraph 6.4.9R(2) of the UK Listing Rules and is presented as a director declaration in the exhibit. The report is dated 02 October 2025 and signed by Amanda Mellor, Company Secretary. The filing reiterates Haleon’s consumer health focus and lists major product categories and brands for context.

Haleon plc has announced the purchase of 1,561,229 ordinary shares under the second tranche of its share buyback programme and intends to hold these shares as treasury stock. After settlement, the company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, with 45,962,012 held as treasury shares, leaving 8,906,391,636 voting shares. The announcement confirms completion of the final tranche of the buyback programme launched 28 March 2025. Since the start of the year, including shares acquired from Pfizer, Haleon repurchased 175,806,525 shares: 131,372,271 were cancelled and 44,434,254 remain as treasury shares. A full trade breakdown is available via the provided link.

Haleon plc reports its total issued share capital and voting rights as of 30 September 2025. The company has 8,952,353,648 ordinary shares of £0.01 each, of which 44,400,783 are held in treasury, leaving 8,907,952,865 ordinary shares with voting rights. Shareholders and others with notification obligations should use 8,907,952,865 as the denominator when assessing disclosure thresholds under the FCA's Transparency Rules. The filing provides a contact for notifiable interests (company.secretary@haleon.com) and a brief company description of Haleon’s consumer health business and major brands.

Haleon plc reports the purchase of 1,500,000 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. The shares were bought on the London Stock Exchange/CBOE on 30 September 2025 at an average price of 331.3782 pence per share and will be held as treasury shares. After settlement the companys registered share capital is 8,952,353,648 ordinary shares, of which 44,400,783 are treasury shares, leaving 8,907,952,865 shares with voting rights. The announcement directs readers to a full breakdown of individual trades online.

Haleon plc announced the purchase of 1,996,340 ordinary shares under the second tranche of its buyback programme. The trades executed on the London Stock Exchange on 29 September 2025 at an average price of £330.3042 per share. The company intends to hold the purchased shares as treasury shares.

After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 42,900,783 are treasury shares, leaving 8,909,452,865 ordinary shares with voting rights. A full breakdown of individual trades is available at the provided RNS link and on the company's investor website.